After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

Patients with cutaneous lupus erythematosus who used hydroxychloroquine had a significantly reduced risk of developing systemic lupus erythematosus.

Lupus Alert Day serves a vital purpose. It encourages others to learn more about lupus, share information on social media, ...

Early initiation of hydroxychloroquine (HCQ) in patients with cutaneous lupus erythematosus (CLE) reduces the risk for progression to systemic lupus erythematosus (SLE) by 87% over time.

Patients with cutaneous lupus erythematosus (CLE), an autoimmune disease that causes skin inflammation, have a higher risk for atherosclerotic cardiovascular disease (ASCVD), or hardening of the ...

Systemic lupus erythematosus, more commonly known as lupus, has a variety of symptoms and room for improvement when it comes to treatment. Cutaneous lupus erythematosus is a common manifestation ...

Systemic lupus erythematosus (SLE) is a complex, chronic, autoimmune disorder that involves multiple organ systems including the skin, joints, heart, lungs, blood, kidneys and, in the most severe ...

RECENT work from this laboratory indicates that patients who have rejected skin homografts manifest a "delayed" type of hypersensitivity to homologous leukocytes. This is evidenced by typical ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ORLANDO ...

Drug-induced lupus is more common in men because they are given these drugs more often; however, not everyone who takes these drugs will develop the disease. Specific criteria for diagnosing ...

Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity and remission, and more time spent in those states, vs. standard therapy ...